DR. EDWARD LEWIS TOBINICK, M.D.
Medical Practice at Ucla Medical Plz, Los Angeles, CA

6595985, Jul 22, 2003

Oct 8, 1999

09/415303

Edward L. Tobinick - Los Angeles CA 90024

A61B 18203

606 9, 606 3, 606 13

A method is provided of removing hair from the skin of a patient using a laser apparatus capable of producing an emission of laser energy in the form of a group of pulses having defined parameters, being a defined pulse group, and using an optical delivery system, which includes the steps of controlling the laser apparatus in each emission of laser energy to emit a defined pulse group of 2 to 15 pulses of coherent light energy; transmitting the defined pulse group of pulses of coherent light energy through an optical delivery system to the same spot on the skin of the patient; irradiating the same spot on the skin containing the hair to be removed with the defined pulse group of coherent light energy transmitted through the optical delivery system from the laser apparatus; controlling the laser apparatus in each emission of laser energy to emit the defined pulse group through the optical delivery system, the defined pulse group having 2 to 15 pulses at a wavelength in the range of 550 to 1200 nm, each pulse at a power level in the range of 2 to 35 Joules/cm per pulse, each pulse having a pulse duration in the range of 1. 2 to 22 milliseconds per pulse, each pulse having a beam diameter on the treatment area in the range of 4 to 50 millimeters, the defined pulse group having a total fluence in the range of 4 to 100 Joules/cm , and a repetition rate of the laser apparatus between successive defined pulse groups being 500 to 2000 milliseconds; and cooling the skin during at least one delay between pulses of the defined pulse group, wherein the at least one delay between pulses is longer to accommodate the cooling step, and wherein the step of cooling is performed by spraying cryogen on the patients skin.

6623736, Sep 23, 2003

May 23, 2002

10/152477

Edward L. Tobinick - Los Angeles CA 90024-6903

A61K 31495

4241341, 514249, 514323

Interleukin (IL) antagonists are provided for the treatment in humans of neurological disorders, trauma, injuries or compression; neurodegenerative disorders including Alzheimers Disease; demyelinating neurological disorders including multiple sclerosis; retinal disorders; and muscular disorders. The IL antagonists are used to treat these disorders by inhibiting the action of IL in the human body. The administration of these IL antagonists is performed by intrathecal administration; intracerebroventricular administration; intranasal administration; by inhalation; or by alternative routes of administration.

6419944, Jul 16, 2002

Apr 5, 2001

09/826976

Edward L. Tobinick - Los Angeles CA 90095-6903

A61F 1300

424422, 424427, 424434, 4241301, 4241341, 4241411, 4241421, 4241451, 435 71, 435 78, 514885, 514913, 514914

Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor; interleukin-1; interleukin-6; and interleukin-8.

2003000, Jan 9, 2003

Sep 6, 2002

10/236097

Edward Tobinick - Los Angeles CA, US

A61K039/395, A61K038/17

424/145100, 514/012000

Methods for treating bone metastases in humans by administering a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1; or biologic inhibitors of osteoclastogenesis, including OPG. The administration of these biologics is performed by specific methods, most of which fall into the category of anatomically localized injection designed for perilesional or intralesional use in proximity to the site of tumor metastasis to bone. Anatomically localized administration involving perilesional or intralesional use includes, but is not limited to, subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or perispinal administration.

6168589, Jan 2, 2001

Apr 3, 1998

9/054574

Edward L. Tobinick - Los Angeles CA

A61B 1818

606 9

A laser apparatus and method for permanently removing a plurality of hair follicles from the skin of a patient. The laser apparatus includes a housing having a single laser for sequentially emitting a series of pulses of coherent light energy having a pulse width in the range of 1/2 ms to 40 ms; a fiber optic bundle connected to the laser for transmitting said series of pulses of coherent light energy to the skin of a patient; and a sequence control device for controlling the laser to emit the series of pulses of coherent light energy sequentially, with a time delay of less than 100 milliseconds between the sequential pulses of the single laser. The laser apparatus includes a handpiece assembly for holding a section of the fiber optic bundle for directing the series of pulses of coherent light energy to the same spot of the patient's skin to remove the plurality of hair follicles, veins, or capillaries.

6177077, Jan 23, 2001

Dec 31, 1999

9/476643

Edward L. Tobinick - Los Angeles CA

A61K 39395

4241341

A method is disclosed for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue or the neuromuscular junction of a human, or for modulating the immune response affecting neuronal tissue or the neuromuscular junction of a human by administering to the human a therapeutically effective dosage level of a TNF antagonist. The TNF antagonist is selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), other agents containing soluble TNF receptors, CDP571 (a humanized monoclonal anti-TNF-alpha antibody), other monoclonal anti-TNF-alpha antibodies, TNF-alpha converting enzyme inhibitors and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue or the neuromuscular junction of a human, or for modulating the immune response affecting neuronal tissue or the neuromuscular junction of a human.

2003011, Jun 19, 2003

Jan 13, 2003

10/340890

Edward Tobinick - Los Angeles CA, US

A61K039/395

424/134100, 424/145100

Methods for treating pre-menstrual syndrome and primary dysmenorrhea in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor alpha. The administration of these biologics is performed by specific methods, including parenteral, intranasal, or anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes.

6015557, Jan 18, 2000

Mar 23, 1999

9/275070

Edward L. Tobinick - Los Angeles CA
Arthur Jerome Tobinick - Los Angeles CA

A61K 39395, A61K 31495, A61K 3150, A61K 3142

4241341

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly. Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

2003018, Oct 2, 2003

Mar 21, 2003

10/393540

Edward Tobinick - Los Angeles CA, US

A61K039/395, A61K038/17

424/145100, 514/012000

Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor.